---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-060883"
form_type: "8-K"
ticker: null
cik: "0001744659"
company_name: "Akero Therapeutics, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:47:37.906728+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akero Therapeutics to raise ~$299M in public offering of 11M shares at $29.00/share

## Summary
- Offering of 11,000,000 shares at $29.00 per share; underwriters have 30-day option for additional 1,650,000 shares.
- Net proceeds expected ~$299.4M (or ~$344.4M if option exercised in full).
- Proceeds to fund clinical development of efruxifermin (EFX) for NASH, including Phase 2b HARMONY and Phase 3 SYNCHRONY studies.
- Cash runway extended into 2027; company currently has no agreements for acquisitions or investments with proceeds.
- Offering expected to close March 8, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001193125-24-060883
- form_type: 8-K
- cik: 0001744659
- company_name: Akero Therapeutics, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/0001193125-24-060883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/d808358d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-060883
- JSON: https://secwatch.observer/filing/0001193125-24-060883.json
- Plain text: https://secwatch.observer/filing/0001193125-24-060883.txt

## Key facts
- Material Agreements
  Akero Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. valued at approximately $299.4 million (effective 2024-03-05).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C.
  - Value: approximately $299.4 million
  - Effective: 2024-03-05
  source text: On March 5, 2024, Akero Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), to the Underwriters at a public offering price of $29.00 per share (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/0001193125-24-060883-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.